Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Rilpivirine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,979Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1
    U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1

    19 Mar 2024

    // PFRESS RELEASE

    https://www.jnj.com/media-center/press-releases/u-s-fda-approves-edurant-ped-rilpivirine-for-certain-pediatric-patients-living-with-hiv-1

    PFRESS RELEASE
    19 Mar 2024
    Share Share
    ViiV Healthcare Announces Data at CROI Indicating Efficacy of Cabenuva
    ViiV Healthcare Announces Data at CROI Indicating Efficacy of Cabenuva

    06 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240305691015/en

    BUSINESSWIRE
    06 Mar 2024
    Share Share
    GSK's injectable HIV drug shows promise over daily pills
    GSK's injectable HIV drug shows promise over daily pills

    22 Feb 2024

    // PRESS RELEASE

    https://www.gsk.com/en-gb/media/press-releases/latitude-phase-iii-interim-trial-data-indicates-cabenuva-has-superior-efficacy-compared-to-daily-therapy/

    PRESS RELEASE
    22 Feb 2024
    Share Share
    ViiV Healthcare receives approval from China’s NMPA for Vocabria
    ViiV Healthcare receives approval from China’s NMPA for Vocabria

    27 Oct 2023

    // PRESS RELEASE

    https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-approval-from-nmpa-for-vocabria-in-combination-with-rekambys/

    PRESS RELEASE
    27 Oct 2023
    Share Share
    Janssen's Rekambys (Rilpivirine) Receives Approval in Europe
    Janssen's Rekambys (Rilpivirine) Receives Approval in Europe

    08 Jun 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/rekambys-epar-medicine-overview_en.pdf

    EMA
    08 Jun 2023
    Share Share
    ViiV Healthcare Announces Positive Data Demonstrating Long-acting Injectable Cabenuva (cabotegravir, rilpivirine) is as Effective as Daily Oral Biktarvy (BIC/FTC/TAF) for the Treatment of HIV-1
    ViiV Healthcare Announces Positive Data Demonstrating Long-acting Injectable Cabenuva (cabotegravir, rilpivirine) is as Effective as Daily Oral Biktarvy (BIC/FTC/TAF) for the Treatment of HIV-1

    23 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230222005673/en

    BUSINESSWIRE
    23 Feb 2023
    Share Share